Navigation Links
MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
Date:11/9/2010

WARREN, N.J., Nov. 9, 2010 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,824,588 from the United States Patent and Trademark Office (USPTO). The patent, issued on November 2, 2010, provides intellectual property protection for the Company's film products and methods of their preparation.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Our patented PharmFilm® and production technologies are very important to ensuring that drug containing films are manufacturable, content uniform, stable and deliver the in-vivo performance that is expected from each and every dose.  Importantly, this patent also signals to the entire pharmaceutical industry that PharmFilm® is an ideal vehicle for delivering a variety of dosage strengths and sensitive prescription drug targets, including peptides and proteins as well as small molecules."

Mr. Schobel continued, "Our patent estate continues to strategically grow thereby affording us and our partners a strong and protected product position within the market."

Keith Kendall, executive vice president and CFO of MonoSol Rx said, "We are a technology company, a partnering company and an innovator.  Our strategy is to apply our technology, alone or in combination with others, to add value to our current and prospective partners.  Continuing to innovate and thereby expand the value and applicability of our PharmFilm® platform is critical to the success of MonoSol Rx.  As such, we invest significant time and resources to broaden and protect our intellectual property, and we believe this latest patent gives us, and by extension our partners, significant competitive advantage."

About MonoSol RxMonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  sublingual film, the first combination sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing.  For existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).  For press releases and other company information visit www.monosolrx.com Contacts:MonoSol Rx:Keith KendallChief Financial Officer(732) 564-5000The Ruth Group (on behalf of MonoSol Rx)Jason Rando (media)(646) 536-7025jrando@theruthgroup.com  Sara Pellegrino (investors)(646) 536-7002spellegrino@theruthgroup.com  
'/>"/>

SOURCE MonoSol Rx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
2. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
3. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
4. Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
5. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
6. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
7. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
8. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
9. Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent
10. Sixth U.S. Patent Issued to Dyadic International
11. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Insight 2022" drug pipelines to their offering. ... Global Immune ... gives comprehensive insight on clinical and non-clinical aspects involved in ... main streamline drugs in the immunotherapy treatment. Report helps to ...
(Date:3/22/2017)... Mar 22, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The ... of around 7.1% over the next decade to reach approximately $129.81 ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ( ... to drug research and development, today announced the ... QSP Day 2017 is a day full of ... systems pharmacology (QSP) community. The focus is to ... de-risking and accelerating drug research and development. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... , ... “A Respectful Response To Atheist Manifesto”: theological refutation ... is the creation of published author Richard Hostetter, a former missionary in Africa ... graduate degrees from Kent State University and the University of Ghana. , Published ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... publication of the first issue of its companion print magazine. The new magazine, ... cosmetic surgery thanks to information provided by board-certified doctors from across the country. ...
(Date:3/22/2017)... ... ... Old School Labs™, makers of the best-selling Vintage line of natural sports ... who trained with Floyd Mayweather, made his professional debut in London in 2003 and ... number of wins in contests in Britain, Germany and the U.S. , “We ...
(Date:3/22/2017)... ... March 22, 2017 , ... Influence Health, the ... solutions have enabled Children’s Hospital of The King’s Daughters (CHKD) to achieve a ... value of a digital marketing approach, the 206-bed pediatric teaching hospital in Norfolk, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... research collaboration to translate advances in basic neuroscience at the BMRI labs into ... collaboration seeks to improve movement, vision, and cognition impaired by stroke, traumatic brain ...
Breaking Medicine News(10 mins):